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1. Introduction
Comparing the nutritional content of food to individual health status, there are several con‐
siderations that can be informative and raise troubling concerns. For many decades, re‐
searchers have investigated the relationships between health status and consumption of
extra virgin olive oil. Extra virgin olive oil (and oleic acid) is considered important for the
prevention and coronary heart disease. While the biomolecular aspects involving G protein
need further research, oleic acid levels in platelets may be a discriminating factor, together
with linoleic and arachidonic acid, for coronary heart disease. There is still a huge debate
regarding the effects of oleic acid alone or in combination with antioxidants.
Coronary Heart Disease (CHD) is the main cause of death and morbidity in industrialized
countries. The incidence of myocardial infarction, however, is highly variable, with lower
rates in Mediterranean countries compared to those in northern Europe, USA, or Australia
[1]. Paradoxically, the low incidence of myocardial infarction occurs in spite of a high preva‐
lence of classical cardiovascular risk factors [2].
Olive oil is the primary source of fat in the Mediterranean diet. The beneficial effects of olive
oil on CHD have now been recognized, and are often attributed to the high levels of mono‐
unsaturated fatty acids (MUFA) [3]. Indeed, in November 2004, the US Federal Drug Ad‐
ministration (FDA) allowed a claim on olive oil labels concerning “the benefits on the risk of
coronary heart disease of eating about two tablespoons (23 g) of olive oil daily, due to the
MUFA in olive oil” [4].
© 2013 Cocchi and Lercker; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. A crucial element for a healthy heart: oleic acid and platelets
Oleic acid, and especially that obtained from pressing olives, is a crucial element in the pre‐
vention of ischemic cardiovascular disease, as has been demonstrated by a series of interna‐
tional scientific activity. Fatty acids other than n-3 Polyunsaturated Fatty Acids (PUFAs) can
interact with the metabolism of eicosanoids and potentially influence platelet function. For
example, there is evidence that diets rich in unsaturated fatty acids, such as linoleic acid and
oleic acid, can also decrease thromboembolic risk by replacing arachidonic acid in platelet
phospholipids, decreasing, at least in vitro, the production of thromboxane A2 [TXA2] and
platelet aggregation. However, there is little conclusive evidence that platelet function in
vivo is affected by diet [5].
Oleic acid has been found to be a potent inhibitor of platelet aggregating factor (PAF) and
serotonin secretion. Consequently, in order to understand the molecular mechanisms of ole‐
ic acid action, the effects of this fatty acid on several biochemical events associated with pla‐
telet aggregation induced by PAF have been investigated. In particular, it has been found
that oleic acid causes a decrease in the levels of phosphatidyl inositide phosphate (PIP) and
PIP2, which is associated with an inhibition of platelet aggregation induced by PAF. These
results suggest that inhibition of the PAF response by oleic acid may be at least one of the
steps involved in signal transduction [6].
Several literature reports have further suggested that olive oil may inhibit platelet function.
This possible effect is of interest for two reasons. First, it may contribute to the apparent an‐
ti-atherogenic effects of olive oil, and second, it may invalidate the use of olive oil as an inert
placebo in studies of platelet function. After exposure to olive oil, platelet aggregation and
TXA2 release decreased, and the content of platelet membrane oleic acid increased signifi‐
cantly; platelet membrane arachidonic acid content was found to significantly decrease. This
suggests that excess of oleic acid impairs the incorporation of arachidonic acid into platelet
phospholipids.
Olive oil also has an inhibitory effect on various aspects of platelet function, which might be
associated with decreased risk for heart disease, although fish intake also plays a protective
role [7].
The beneficial effects of olive oil can be attributed to its high content of oleic acid (70-80%).
The consumption of olive oil increases the levels of oleic acid in cell membranes, which
helps to regulate the structure of membrane lipids through the control of signal-mediated G-
protein, causing a reduction in blood pressure [8].
In rats, cardiovascular tissues treated with 2-OHOA (hydroxy oleic acid) show activation of
cAMP in response to activation of Gsα protein, which can be attributed to increased expres‐
sion of Gsα proteins. As a result, there is significant reduction in systolic blood pressure [9].
The involvement of Gs alpha protein is also of interest considering the hypothesis forward‐
ed by Cocchi, Tonello, Rasenick and Hameroff in psychiatric disorders as depression, sui‐
cide etc. (private meeting, 2008). In light of the below model, the role of Gsα protein in
ischemic heart disease merits further investigation.
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Figure 1. Description of selected biochemical and biomolecular events potentially involved in psychiatric disorders.
In figure 1, the molecular depression hypothesis described by Cocchi et al. [10], Donati et al.
[11] and Hameroff and Penrose [12] is shown. Because of the possible similarity of the plate‐
let to neurons, membrane viscosity can modify Gsα protein status. The Gsα protein is asso‐
ciated with tubulin. Depending on local membrane lipid composition, tubulin may serve as
a positive or negative regulator of phosphatidylinositol bisphosphate hydrolysis (PIP2) simi‐
lar to G proteins. Tubulin is known to form high-affinity complexes with certain G proteins.
The formation of these complexes allows tubulin to activate Gsα protein and creates a sys‐
tem whereby elements of the cytoskeleton can influence G-protein signaling. Rapid changes
in membrane lipid composition or the cytoskeleton can modify neuronal signaling through
such a mechanism.
Protein kinase C (PKC) activation (Figure 2) is preceded by a number of steps, originating
from the binding of an extracellular ligand that activates a G-protein on the cytosolic side of
the plasma membrane. This G-protein, using guanosine triphosphate (GTP) as an energy
source, then activates protein kinase C (PKC) via the phosphatidylinositol bisphosphate
(PIP2) intermediate, which is shown as the diacylglycerol DAG/IP3 complex. Several studies
have shown that a reduced functionality of the serotonin (5-HT) transporter in some psychi‐
atric disorders, such as obsessive-compulsive disorder (OCD), may be related to alterations
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in its regulation at an intracellular level. PKC has also been reported to provoke a decrease
in the number of 5-HT transporter proteins. The increased activity of PKC in OCD may be
the result of increased activity of the phosphatidylinositol pathway.
Figure 2. Description of PKC activation. Adapted from Alberts et al. [13].
The exclusive use of olive oil during food preparation seems to offer significant protection
against ischemic heart disease, in spite of poor clinical conditions, lifestyle and other charac‐
teristics of individuals [14]. In addition, several historical papers have reported on the posi‐
tive effects of olive oil on CHD.
In 1985, Mattson and Grundy [15] reported that olive oil reduces HDL cholesterol, which
plays a protective, anti-atherogenic function, favoring the elimination of LDL-cholesterol. In
1986, Sirtori et al. [16] have shown that in addition to its effects on cholesterol and athero‐
sclerosis, olive oil has preventive action on thrombosis and platelet aggregation. High intake
of olive oil is not harmful, and reduces the levels of LDL-cholesterol, but not HDL [17 - 25].
3. Oleic acid and Atherogenesis
Atherosclerosis is considered to be an inflammatory disease [26], and endothelial dysfunc‐
tion occurs early in the development of the pathology. Traditional risk factors for atheroscle‐
rosis promote endothelium activation, which induces adhesion and trans-endothelial
migration of monocytes [26]. Several inflammatory mediators are released by the endotheli‐
um such as the eicosanoids derived from n-6 PUFA arachidonic acid. These include prosta‐
glandin E2 (PGE2), leukotriene B4, a chemoattractant and neutrophile activator,
thromboxane, a potent vasoconstrictor, and platelet-aggregating factor [27].
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Monocytes and macrophages are critical cells present in all stages of atherosclerosis. In addi‐
tion to promoting LDL oxidation through free radical production, they also secrete proin‐
flammatory cytokines such as IL-1 and Tumor Necrosis Factor (TNF), which stimulate the
expression of adhesion molecules such as intercellular cell adhesion molecule-1 (ICAM-1),
vascular-cell adhesion molecule-1 (VCAM-1), and E-selectin [25]. Circulating monocytes are
attracted by these molecules and adhere to the endothelium, from which they transmigrate
to the subendothelial space. Once within the endothelium, monocytes differentiate into mac‐
rophages, which in turn scavenge oxidized LDL, thus becoming foam cells and lead to pla‐
que formation.
The proinflammatory response releases a principal messenger from macrophages, namely
cytokine IL6. After engagement of its receptor on the liver, IL6 promotes the secretion of C
Reactive Protein (CRP), a prototypic marker of inflammation [28, 29]. Serum IL6 and CRP
have been shown to be predictive of CHD. Altered levels of serum CRP, IL6, and ICAM-1
have been associated with progression of atherosclerosis, and IL6 has been shown to be a
good predictor of progressive peripheral atherosclerosis [30, 31].
The inflammatory protection of diets rich in oleic acid has been attributed to a decrease in
the content of LDL linoleic acid [32]. The low susceptibility of oleic acid to oxidation, and
the scavenging capacity of minor compounds in olive oil, can decrease the activation of pro-
inflammatory transcription factors, such as nuclear factor-kappa B (NFkB), through a reduc‐
tion of reactive oxygen spices and peroxyl radicals [33]. In this regard, it has been reported
that consumption of meals enriched in olive oil do not activate NFkB in monocytes in con‐
trast to meals rich in butter and walnut-enriched meals [34]. Studies on oleic acid enriched
liposomes and vascular endothelium exposed to oleic acid, however, suggest a protective
mechanism of oleic acid on free radical generation, oxidative damage to lipids, and inflam‐
matory activity [35, 36].
Recent data suggest that oleic acid is not the only agent responsible for the anti-inflammato‐
ry properties of olive oil. In experimental studies, minor components of the unsaponifiable
fraction of olive oil, such as alfa-tocopherol, beta-sitosterol, and triterpenes, in addition to
phenolic compounds, have all been shown to have both anti-inflammatory and anti-endo‐
thelial activation properties [37]. The results of a meta-analysis of 14 studies carried out dur‐
ing 1983–1994 showed that the replacement of SFA by oils enriched in MUFA or PUFA had
similar effects on total, LDL, and HDL cholesterol, whereas PUFA-enriched oil had a slight
triglyceride-lowering effect [38]. Dubois et al. [39] showed that increasing the amount of fat
up to 50 g led to stepwise increases in the postprandial rise of serum triglycerides, while the
ingestion of 15 g fat had no effect on postprandial lipemia or lipoproteins in healthy adults.
A meal containing 31 g of fat induced considerably less variations in lipemia, chylomicrons,
and lipoproteins than a 42 g fat meal [39]. A single dose of 25 mL olive oil was not found to
promote postprandial lipemia [40], in contrast to 40 mL and 50 mL doses [41, 42] with no
effect on the phenolic content of the olive oil.
Abia et al. [43] reported that virgin olive oil intake resulted in lower postprandial triacylgly‐
ceride-rich-lipoprotein (TRL) levels and a faster disappearance of TRL-TG from blood, com‐
pared to intake of sunflower oil with a high content of oleic acid. Chylomicrons produced
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after olive oil [44, 45] or n-3 PUFA [46] ingestion seem to enter the circulation more rapidly,
and cleared at a faster rate, in comparison to those produced after intake of fats rich in SFA
or PUFA. Although fat intake appears to be the major nutritional determinant of the post‐
prandrial triglyceride response, it is also influenced by other dietary components, including
fiber, glucose, starch, and alcohol in a meal [47].
The oxidative modification of LDL plays a key role in development of atherosclerosis and
CHD. Oxidation of lipids and lipoproteins present in LDL leads to a change in the lipoprotein
conformation by which LDL are more facilitated to enter the monocyte/macrophage system of
the arterial wall, and promote the atherosclerotic process [48]. It is currently believed that oxi‐
dized LDL are more damaging to the arterial wall than native LDL [49]. Elevated concentra‐
tions of circulating oxidized LDL show a positive relationship with the severity of acute
coronary events [50, 51]. They are also independently associated with carotid intima-media
thickness [52] and are predictors for CHD both in CHD patients [53] and the general popula‐
tion [54]. Several studies have been performed comparing the effects of MUFA-rich diets on
the susceptibility of LDL to oxidation with those of PUFA- or carbohydrate-rich diets. Oleate-
rich LDL have been shown to be less susceptible to oxidation than linoleate rich LDL [55-61].
4. Depression and Ischemic Heart Disease: a common role for oleic acid?
Because of the particular role of platelets on depressive and thrombogenetic risk, our group
has investigated the platelet fatty acid profile in three groups of subjects: healthy (n=60), is‐
chemic (n= 50) and depressive (n= 84). The aim of the study was to understand which fatty
acid could be utilized as markers of ischemic cardiovascular pathology and depressive dis‐
order, and to classify subjects using an artificial neural network (ANN). All the ANNs tested
gave essentially the same result. However, one type of ANN, known as Self-Organizing
Map (SOM), [62, 63, 64], gave additional information by allowing the results to be described
in a two-dimensional plane with potentially informative border areas. The central property
of the SOM is that it forms a nonlinear projection of a high-dimensional data manifold on a
regular, low-dimensional (usually 2D) grid.
A series of repeated and independent SOM simulations, with the input parameters being
changed each time, led to the finding that the best discriminating map was that obtained by
inclusion of the following three fatty acids: palmitic acid (C16:0), linoleic acid (C18:2 n-6)
and arachidonic acid (C20:4 n-6) for depressive subjects and oleic acid (C18:1), linoleic acid
and arachidonic acid for ischemic subjects [10, 65-67] (Figures 3, 4).
5. A case study
A 42-year-old female with a very high familial risk for ischemic cardiovascular disease (one
sister 34 years old died of heart attack; another sister, 48 years old, heart attack; uncle, two
infarctions; mother, 69 years old, died of heart attack; aunt, 59 years old, died of heart at‐
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tack), was submitted to a classic complete functional cardiovascular investigation which re‐
sulted negative. The subject is a heavy smoker, cholesterol: 230 mg/dl, HDL: 84 mg/dl.
Framingham score: 13 (low risk score). Platelet levels of oleic acid, linoleic acid and arachi‐
donic acid were analyzed using the SOM designed for ischemic patients, and the concentra‐
tions of those fatty acids were entered in the SOM. The subject detailed information on the
study and provided informed consent. The patient’s fatty acid triplet, tested in the SOM,
gave the following result (Figure 5).
Figure 3. SOM classification of depressive subjects (red) against normal subjects (green). Platelet arachidonic acid
(C20:4), palmitic acid (C16:0), and linoleic acid (C18:2) can discriminate depression and have diagnostic power.
Figure 4. SOM classification of ischemic subjects (red) against normal subjects (green). Platelet oleic acid (C18:1), arachi‐
donic acid (C20:4), linoleic acid (C18:2) can discriminate ischemia and have diagnostic power.
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Figure 5. Position of the patient according to the three fatty acids (oleic, linoleic and arachidonic) on the SOM, which
classifies ischemic patients.
This result was compared with the SOM classification of normal and pathologic subjects, as
shown in figure 4. The patient was asked to submit herself to a Coronary TAC and the im‐
ages showed ”Interventricular Anterior (IVA) branch: small mixed plaque in the proximal
tract, 33% of the lumen” (radiological diagnosis). The result suggests the opportunity to se‐
lect young high risk subjects to evaluate not only the diagnostic power of the SOM, but also
the possibility for early diagnosis of plaque formation. A large trial is necessary to validate
this result, but based on the classical rules of Evidence Based Medicine, it is very difficult to
obtain approval from an ethic’s committee.
Medical science has not yet fully understood or accepted the use of the ANN mathematic
models in relation to experimental conditions, which are still strongly linked to traditional
protocols. The task of finding biomarkers according to the rules dictated by Evidence Based
Medicine requires the elimination of selection bias, and leads to selection of a population
that may be clinically unrealistic. The characteristics of the above-described method none‐
theless allow the analysis to be carried out, and permit to find differences among subsets of
the population.
The first fundamental consequence of the use of fatty acids is that an extremely effective and
practical diagnostic tool can be obtained, with a strong tolerance to “noise”. Secondly, the
choice of specific fatty acids and their relative strength in the classification by the SOM al‐
lows investigating more in-depth investigation of the problem and helps in understanding
the disease from the biochemical point of view.
6. Commonalities between CHD and depression
To demonstrate the powerful grouping capacity of the SOM, we created a new network
where all three groups were inserted and grouped simultaneously on the basis of the char‐
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acteristics of the triplets previously highlighted, which were all different from one another
[68] (Figure 6).
 
Figure 6. Simultaneous classification, using the SOM, of three groups of subjects (normal, depressive and ischemic). In
the right corner of the map, ischemic and depressive subjects are mixed and have, in common, a low level of platelet
oleic acid.
As shown by the SOM, it is possible that reduced amounts of oleic acid not only are critical
in the biochemical classification of ischemic heart disease, but are also common to a condi‐
tion that characterizes a relationship between depression and ischemia [69]. It seems possi‐
ble that levels of C18:1 in platelets dominate in ischemia, and are linked to depression.
Furthermore, it can be conjectured that there are two different types of depression, namely
classical and ischemia-induced according to the findings of different platelet membrane vis‐
cosity and its effect at the biomolecular level. [10-12, 70]. The relationships between depres‐
sion and ischemic heart disease have been widely studied [71, 72]. Interestingly, Weyers and
Colquhoun [73] reported improvements in depressive symptoms in patients with CHD after
consumption of olive oil.
7. Do we eat enough extra virgin olive oil?
The question then arises as to whether there is sufficient consumption of olive oil and oleic acid
in the Italian population. Knowing that oleic acid can significantly change the composition of
platelet fatty acids, which are crucial in the genesis of plaque formation, and can significantly
alter the amount of oleic acid in platelet membranes, an experiment on a large group of pigs (80
Duroc x Large White) was performed [74]. Four groups of pigs were studied, 20 animals each,
which received four diets containing different lipid fractions, as follows:
Diet 1: corn oil (low linoleic acid.), diet 2: corn oil (medium linoleic acid.), diet 3: sunflower oil
(high oleic acid.), diet 4: sunflower oil (high oleic acid) + palm oil (high palmitic acid). The di‐
ets fed to animals, to meet the needs for growth, had the following lipid composition (Table 1):
Reduced Consumption of Olive Oil: A Risk for Ischemic Heart Disease?
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Period (kg) Diet EE C16:0 C18:0 C18:1n9 C18:2n6 C18:3n3
50 - 90 1 2.70 13.13 2.05 31.07 50.90 2.59
50 - 90 2 2.86 14.37 2.04 26.40 54.54 2.42
50 - 90 3 5.30 8.91 2.39 56.47 30.23 1.27
50 - 90 4 5.37 18.67 8.36 39.99 30.86 1.40
90 - 120 1 2.63 12.83 1.72 31.60 51.15 2.38
90 - 120 2 2.57 14.16 1.94 25.76 54.96 2.55
90 - 120 3 5.56 8.81 2.44 57.12 29.73 1.26
90 - 120 4 5.62 20.02 9.26 39.41 29.59 1.12
120 - 160 1 2.83 13.32 1.69 30.46 52.00 2.41
120 - 160 2 2.89 13.75 1.88 25.65 56.29 2.35
120 - 160 3 5.74 8.54 2.10 57.18 30.91 1.07
120 - 160 4 5.76 19.71 9.25 39.16 30.25 1.17
Table 1. Ether extract (% dry Matter) and fatty acid composition of lipid fractions
Fatty Acids C16:0 C18:0 C18:1n9 C18:2n6 C18:3n3 C20:4
Diet 1 Media s.d.
28.51a 32.00 17.38 B 9.30 0.63a 12.19 AB
1.84 10.70 5.63 3.40 0.36 5.18
Diet 2 Media s.d.
27.73 ab 29.01 18.0 B 9.07 0.48ab 15.6 A
1.47 8.48 3.17 2.88 0.29 4.52
Diet 3 Media s.d.
27.00ab 27.78 24.93 A 9.37 0.34b 10.59B
2.07 8.12 6.78 3.10 0.25 4.48
Diet 4 Media s.d.
26.51b 32.04 19.36 B 9.32 0.51ab 12.25AB
2.63 11.07 5.43 3.64 0.32 4.27
P <0.05 n.s. <0.01 n.s. <0.05 <0.01
Table 2. Mean values ± SD of platelet fatty acids in the different treatment groups
The platelet fatty acids (Table 2) were plotted as for ischemic and normal human subjects in
the SOM for ischemia (Figure 7).
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Figure 7. By increasing the oleic acid content in diets is possible to move pig platelets, in agreement with the fatty
acid triplet [66, 67], from the pathologic (red area) to the normal (green area) area.
It is feasible to obtain similar results in humans. If one considers the characteristics descri‐
bed for the pig model of atherosclerosis [75], and applying similar characteristics to humans,
it can be assumed that we should consume a quantity of oleic acid, and consequently, extra
virgin olive oil, that is at least twice that of current levels. To demonstrate this, we made
simple considerations based on the purchase of olive oil in Italy (Data provided by the Isti‐
tuto di Servizi per il Mercato Agricolo Alimentare (ISMEA).
Based on data provided and taking into account that the value derived from the table
should be increased by 40%, since about 40% of purchase data were excluded, the consump‐
tion of extra virgin olive oil for each Italian is on average, about 11.76 grams of oleic acid
daily, considering that olive oil is on average value about 70% oleic acid. This value is even
likely to be less, as much oil is also used for frying, and therefore cannot be included as part
of raw consumption. While this quantity is very small, there are also regional differences be‐
tween the north and south of Italy.
This observation is also related to the observation that current eating behavior does not al‐
low large consumption of olive oil. It should be remembered that meals eaten out of the
household, often consisting of a sandwich, make it difficult to consume extra virgin olive oil
in larger quantities. While the eating habits of rural areas may still be able to compensate
this situation, there is an increasing trend to gradually move away from such traditions.
Recently, we investigated the consumption of olive oil in a restaurant in the Center-North of
Italy, (2750 subjects in one month). The average consumption of olive oil was 1.8 g per cus‐
tomer per month, which corresponds to about 1.26 g of oleic acid. Together with the above
cited data, this results confirms that olive oil is not consumed in large quantities. Given this,
as Ancel Keys pointed out, one wonders if the Mediterranean diet is still a model of health,
considering the consumption of extra virgin olive oil.
Reduced Consumption of Olive Oil: A Risk for Ischemic Heart Disease?
http://dx.doi.org/10.5772/54035
13
Systematic name Trivial name Shorthanddesignation
Molecular
weight Melting point (°C)
butanoic butyric 4:0 88.1 -7.9
pentanoic valeric 5:0 102,1 -19
hexanoic caproic 6:0 116.1 -3.4
octanoic caprylic 8:0 144.2 16.7
nonanoic pelargonic 9:0 158.2 12.5
decanoic capric 10:0 172.3 31.6
dodecanoic lauric 12:0 200.3 44.2
tetradecanoic myristic 14:0 228.4 53.9
hexadecanoic palmitic 16:0 256.4 63.1
heptadecanoic margaric (daturic) 17:0 270.4 61.3
octadecanoic stearic 18:0 284.4 69.6
eicosanoic arachidic 20:0 312.5 75.3
docosanoic behenic 22:0 340.5 79.9
tetracosanoic lignoceric 24:0 368.6 84.2
cis-9-hexadecenoic palmitoleic 16:1(n-7) 254.4 0.5
cis-9-octadecenoic oleic 18:1(n-9) 282.4 16.2
trans-9-octadecenoic elaidic tr18:1(n-9) 282.4 43.7
cis-11-octadecenoic cis-vaccenic (asclepic) 18:1(n-7) 282.4 39
cis-9-eicosenoic gadoleic 20:1(n-11) 310.5 25
cis-13-docosenoic erucic 22:1(n-9) 338.6 33.4
9,12-octadecadienoic linoleic 18:2(n-6) 280.4 -5
6,9,12-octadecatrienoic γ-linolenic 18:3(n-6) 278.4
9,12,15-octadecatrienoic α-linolenic 18:3(n-3) 278.4 -11
8,11,14-eiosatrienoic dihomo-γ-linolenic 20:3(n-6) 306.5
5,8,11,14-eicosatetraenoic arachidonic 20:4(n-6) 304. -50
6,912,15-octadecatetraenoic stearidonic 18:4(n-3) 276.4 -57
5,8,11,14,17-eicosapentaenoic EPA 20:5(n-3) 302.5 -54
7,10,13,16,19-docosapentaenoi DPA 22:5(n-3) 330.6
4,7,10,13,16,19-docosahexaenoic DHA 22:6(n-3) 328.6 -44
(see: http://216.239.59.104/search?q=cache:qTHq_xfePkIJ:www.cyberlipid.org/fa/acid0001.htm+Aitzetm
%C3%BCller+K&hl=it)
Table 3. Selected chemical and physical characteristics of fatty acids
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8. Chemical and technological considerations about oleic acid
Fatty acids have different functions in living organisms, including the structural one, which
are determined by the length of their hydrocarbon chain and the presence or absence of
double bonds. Hydrocarbon chain length, in the same conditions of unsaturation, is directly
proportional to the melting point (as well as the boiling point) (Table 3). The solubility in
water (Table 4) and unsaturation, for the same chain length, is inversely proportional to the
melting point (see Table 3), with very few exceptions.
Carbon number Solubility
2 Infinite
4 Infinite
6 9.7
8 0.7
10 0.15
12 0.055
14 0.02
16 0.007
18 0.003
Table 4. Fatty acid solubility in water at 20°C (in grams per liter)
These chemical differences are determined in large part by chemical and physical interac‐
tions that exist when molecules are close enough to unsaturate them. In the case of fatty
acids, the possibility to join molecules depends only on the hydrocarbon chain (Van der
Waals forces), which is facilitated when it is saturated and more difficult when unsaturated
(especially at the point of unsaturation). The longer and more linear the chain, the greater
the interaction, and the more unsaturated it will be, consequently, the interaction will be
lower. When fatty acids are part of a triglyceride or phospholipid, the effect occurs in a simi‐
lar manner and therefore, in biological membranes, a greater or lesser chance of interaction
corresponds to greater or lesser "fluidity" of the membrane, which is proportional to more or
less functionality (permeability).
At room temperature, in terms of membrane structure, fatty acids are important, and the
ones that are more widespread in nature are those with 18 total carbon atoms, especially un‐
saturated. Modulation of proper membrane fluidity requires that some fatty acids are rela‐
tively "rigid", such as palmitic and stearic acid, with a preference for the former since it has a
lower melting point and thus is more effective in bringing about small changes.
One of the most important aspects of biological systems that protect themselves through
membranes is the preservation of integrity of the membrane itself, which is subject to con‐
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tact with chemical reactive oxygen species (ROS), and capable of chemically attacking the
unsaturated zone of the molecule. Greater effectiveness is related to a greater level of unsa‐
turation, leading to subsequent breakage of the molecule with increased membrane fragility.
For these reasons, the membrane is associated with a series of antioxidants, whose action is
linked to their position in the membrane [75]. Oleic acid is the least oxidizable among unsa‐
turated fatty acids (Table 5), and is also not too fluid or too rigid, and is thus suitable for
prolonging membrane stability [76, 77].
FATTY ACID 1) AUTOXIDATION 2) AUTOXIDATION
PHOTOSENSITIZED
OXIDATION
(PHOTOXIDATION)
SATURATED 1 1
MONOENES 10 100 1.1 (32,000)*
DIENES 100 1200 2.9 (1600)*
TRIENES 200 2500 3.5
TETRAENES** 300
PENTAENES** 400
HESAENES** 500
* In brackets ratio between photoxidation and autoxidation is shown
** Hypothesis based on physical-chemical behavior
Table 5. Oxidation rate of several unsaturated fatty acids [Modified from Gunstone et al. [76]]
The rate of oxidation between various unsaturated fatty acids shown in Table 5 appears in‐
creased between oleic acid (monoenes) and linoleic acid (dienes), but upon increasing the
unsaturation (trienes), the variation is much less pronounced. In biological systems, the po‐
sition of the fatty acid in glycerides or phospholipids [77] appears to influence the rate of
oxidation, and is slower when inserted in position 2, or in the β position of the molecule. In
the case of olive oil, as in all vegetable fats (Table 6), the 2 position is occupied by unsaturat‐
ed fatty acids, and is more available in that position because it can directly cross the intesti‐
nal wall of the 2-monoglycerides, resulting from digestion of glycerides by pancreatic lipase.
In particular, on a molar basis, 83% of unsaturated fatty acids, in position 2 of triglycerides
in olive oil, is occupied by oleic acid.
For extra virgin olive oil, its total unsaturation makes it particularly stable (Table 7) [79, 80]
so that appropriate conservation, which is further prolonged by the presence of numerous
and effective natural antioxidants (biophenol), is still present after refining, in contrast to
other oils.
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Fat or Oil source Fatty acid position 14:0 16:0 18:0 18:1 18:2 18:3 20:0 22:0
Women milk*
1 3.2 16.1 15.0 46.1 11 0.4
2 7.3 58.2 3.3 12.7 7.3 0.6
3 7.1 6.2 2.0 49.7 2.0 1.6
Women milk
1 18.2 20.0 73.9 42.5 33.3 15.4
2 41.5 72.3 16.3 11.7 22.1 23.1
3 40.3 7.7 9.9 45.8 44.5 61.5
Cow milk
1 11 36 15 21 1
2 20 33 6 14 3
3 7 10 4 15 <1
Pig
1 1 10 30 51 6
2 4 72 2 13 3
3 7 73 8
Cow
1 4 41 17 20 4 1
2 9 17 9 41 5 1
3 1 22 24 37 5 1
Cocoa butter
1 34 50 12 1
2 2 2 87 9
3 37 53 9
Groundnut
1 14 5 59 18 1 -
2 1 <1 58 39 - -
3 11 5 57 10 4 6
Corn
1 18 3 27 50 1
2 2 <1 26 70 <1
3 13 3 31 51 1
Soya
1 14 6 23 48 9
2 1 1 21 70 7
3 13 6 28 45 8
Olive
1 13 3 72 10 <1
2 1 - 83 14 1
3 7 4 74 5 1
Mol % = molar percentage
*Relative GC area % (http://www.cyberlipid.org/index.htm); ** Sørensen A.D.M. et al., 2010 [78]
Table 6. Main fatty acid (mol %) distribution in the three positions of glycerine molecule of the corresponding
triacylglycerols (triglycerides) of several fats and oils.
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Fattyacids
Caprylic
(C8:0)
Capric
(C10:0)
Lauric
(C12:0)
Mirystic
(C14:0)
Palmitic
(C16:0)
Stearic
(C18:0)
Oleic
(C18:1)
Linoleic
(C18:2)
Linolenic
(C18:3)
Eicosenoic
(C20:1)
Total
Unsaturationa
(unstability
factor)
Iodine
number
Oil from:
Groundnut ND-0.1 8.0-14.0 1.0-4.5 35.0-69.0 12.0-43.0 0-0.3 0.7-1.7 200-481 86-107
Rapeseed (0
erucic)
ND-0.2 2.5-7.0 0.8-3.0 51.0-70.0 15.0-30.0 5.0-14.0 0.1-4.3 320-630 105-126
Safflower ND-0.2 5.3-8.0 1.9-2.9 8.4-21.3 67.8-83.2 ND-0.1 0.1-0.3 700-740 136-148
Safflower (HO) ND-0.2 3.6-6.0 1.5-2.4 70.0-83.7 9.0-19.9 ND-0.2 0.1-0.5 175-270 80-100
Sunflower ND-0.1 ND-0.2 5.0-7.6 2.7-6.5 14.0-39.4 48.3-74.0 0-0.3 0-0.3 531-766 118-141
Sunflower (HO) ND-0.1 2.6-5.0 2.9-6.2 70.0-90.7 2.1-20.0 ND-3.0 0.1-0.5 118-270 78-90
Corn ND-0.3 ND-0.3 8.6-14.0 ND-3.3 20.0-42.0 34.0-65.6 0-1.2 0.2-0.6 400-481 103-135
Olive (CODEX) 7.5-20.0 55.0-83.0 3.5-21.0 Max 1.0 Max 0.4 163-285 75-94
Soya Bean ND-0.1 ND-0.2 8.0-13.5 2.5-5.4 17.0-30.0 48.0-59.0 4.5-11.0 0-0.5 600-840 124-139
Grape seed ND-0.3 5.5-11.0 3.0-6.5 12.0-28.0 58.0-78.0 0-1.0 0-0.3 596-802 128-150
Fat from:
Cocoa butter 22.6-30.4 30.2-36.0 29.2-36.4 1.3-4.0 ND-0.5 370-380 34-40
Coconut 4.6-10 5.0-8.0 45.1-53.2 16.8-21.0 7.5-10.2 2.0-4.0 5.0-10.0 1.0-2.5 ND-0.2 ND-0.2 24-34 6.3-10.6
Palm ND-0.5 0.5-2.0 39.3-47.5 3.5-6.0 36.3-44.0 9.0-12.0 ND-0.5 ND-0.4 130-391 50.0-55.0
Palm olein 0.1-0.5 0.5-1.5 38.0-43.5 3.5-5.0 39.8-46.0 10.0-13.5 ND-0.6 ND-04 158-187 56
Palm stearin 0.1-0.5 1.0-2.0 48.0-74.0 3.9-6.0 15.5-36.0 3.0-10.0 ND-0.5 ND-0.4 76-270 33
Palm kernel 2.4-6.2 2.6-5.0 45.0-55.0 14.0-18.0 6.5-10.0 1.0-3.0 12.0-19.0 1.0-3.5 ND-0.2 ND-0.2 33-51 14.1-21.0
a Total unsaturation is calculated as the relative percentage of single fatty acid for a different factor, for each unsatura‐
tion, the degree is proportional to the oxidative instability. The factors utilized were: 1 for monounsaturated, 10 for
diunsaturated and 20 for triunsaturated fatty acids. HO =high oleic. ND = not detectable
Table 7. Main fatty acid composition of fats and oils
Not all olive oils have the same concentration of oleic acid. The International Olive Oil
Council (IOOC) has dictated that the content of oleic acid in olive oils can vary from 55% to
83% of total fatty acids [81]. The regulations of the European Community do not indicate the
amount of oleic acid in olive oil, but simply indicate the specifications of several other pa‐
rameters that are useful for detecting fraud and require the distinction between various
commercial products obtained from olive processing.
Among these, extra virgin oils are those that must have the highest quality. Extra virgin
olive oils with the highest content of oleic acid have always been regarded as those with the
highest quality, but only because of their higher stability during storage, as a consequence of
the low reactivity of oleic acid compared with polyunsaturated fats. The Food and Drug Ad‐
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ministration (FDA) has stated (November 1, 2004) that U.S. consumption of 23 g of olive oil
each day (about two tablespoons) helps in prevention of cardiovascular diseases [4].
Today, there are other sources of oil high in oleic acid, such as safflower, sunflower and can‐
ola (the new name for rapeseed oil low in erucic acid), and therefore based solely on the con‐
tent of oleic acid, these sources would also be optimal in this regard. However, the
reputation of olive oil as a healthy product is most likely due to the presence of the numer‐
ous "minor elements" contained within [82, 83]. Among these minor components, several
compounds are worthy of mention including biophenols, which consists of phenols and pol‐
yphenols with high antioxidant and antiradical activity, some triterpene alcohols, phytoster‐
ols, squalene, and tocopherols. These latter are considered important because of the content
of vitamin E, and for their ability to facilitate the assimilation of polyunsaturated fatty acids:
1 mg allows the assimilation of 1 g of polyunsaturated fatty acids [84].
The discovery of health effects from the minor components in olive oil has led to a large gap
in the nutritional properties of edible oils. In fact, oils from seeds, subject to refining, loose
many minor components and do not have the health properties that the corresponding ma‐
trix has. The technology for olive processing influences the quality and organoleptic charac‐
teristics of the final product, which is not always considered by industrial operators as much
of the scientific knowledge is particularly new. The olive oil is encapsulated in small drops
(10-30 micrometers) within vacuoles with a polysaccharide wall: oil droplets, during proc‐
essing, are released in crushing and come into contact with the other components of olives
during grinding of the paste. It is the prolonged contact with the oil-pasta that allows join‐
ing of small droplets such that they can then leave the dough during the separation process
that emulsifies all the minor components in oil.
Therefore, time and temperature of processing can also affect the final product, and even if
the starting characteristics of the olives are similar they can yield very different products.
Moreover, during the same oil-paste stage, enzyme activities are capable of forming the fra‐
grance of the oil through a series of biochemical steps that, in part, may reduce the antioxi‐
dant ability of biophenol components and their effects on health. Therefore, choices made
during the processing of olives should take these effects into consideration.
There are several hundred olive cultivars grown in Italy, which can produce many oils that
have a very different composition, although all can be considered of excellent quality. In
particular, the richness in antioxidants (especially biophenols) can affect characteristics of
the oil in terms of taste, storage stability, and health properties. Even if much scientific
knowledge has been learned about olive production and processing technology, there are
still many questions that must be answered in order to improve the quality, especially those
related to health, of the oils obtained by processing olives
9. Conclusion
The ability to transform, by the action of delta9-desaturase, stearic acid to oleic acid, and
vice versa makes oleic acid very useful for the modulation of the fluidity (and functionality)
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of cell membranes. Recalling that the fatty acid composition of platelets can be correlated
with depression and also with ischemia [85], we can consider the oil obtained from olive
processing such as the lipid substrate better balanced with respect to the fatty acid unsatura‐
tions, for the platelet membrane composition of normal individuals.
We must remember that the presence of high concentrations of oleic acid from olive oil is
one of the stabilizing factors against oxidative modification, in both cases, for the oil itself
and for cell membranes. Furthermore, the oil from olives when is classified as extra virgin,
possesses a wealth of biophenols, powerful antioxidants predominantly of antiradical type,
which further increase the stability of the oil and, more or less directly, even of the mem‐
brane lipids.
Olive oil, and, particularly an extra virgin olive oil-rich diet, decreases prothrombotic activi‐
ty, and modify platelet adhesion, coagulation, and fibrinolysis. The wide range of antia‐
therogenic effects associated with olive oil consumption can help to justify the low rate of
cardiovascular mortality found in southern European Mediterranean countries, in compari‐
son with other western countries, despite a high prevalence of CHD risk factors. Experimen‐
tal evidence confirms a critical role of reduced levels of oleic acid in platelets in ischemic
subjects with a diagnostic discriminant capacity from normal subjects [85]. At present, al‐
though traditional cardiovascular risk factors are under revision, a new field of research in
platelets, and in particular oleic acid and its relationship with linoleic and arachidonic acid,
should be pursued. The mechanisms by which olive oil exerts its beneficial effects merit fur‐
ther investigation, and additional studies are required to document the benefits of olive oil
consumption on primary endpoints for cardiovascular disease. In this regard, consumption
of extra virgin olive oil and daily intake of oleic acid should, however, be promoted.
Author details
Massimo Cocchi1,2 and Giovanni Lercker3
1 “Paolo Sotgiu” Institute for research in Quantitative & Quantum Psychiatry & Cardiology,
L.U.de.S University, Lugano, Switzerland
2 Department of Medical Veterinary Sciences, University of Bologna, Italy
3 DISA, University of Bologna, Italy
References
[1] Tunstall-Pedoe, H. Kuulasmaa, K. Mahonen, M. Tolonen, H. Ruokokoski, E.
Amouyel, P. Contribution of trends in survival and coronary-event rates to changes
in coronary heart disease mortality: 10-year results from 37 WHO MONICA project
What Should We Know About Prevented, Diagnostic, and Interventional Therapy in Coronary Artery Disease20
populations. Monitoring trends and determinants in cardiovascular disease. Lancet,
1999, 353: 1547–57.
[2] Masia, R. Pena, A Marrugat, J. Sala, J. Vila, J. Pavesi, Covas, M. Aubo, Elosua, C. R.
High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low
myocardial infarction incidence. REGICOR Investigators. J Epidemiol Community
Health, 1998, 52: 707–15.
[3] Covas, MI. Olive oil and the cardiovascular system. Pharmacological Research, 2007,
55: 175–186.
[4] US Food and Drug Administration. Press Release P04-100. November 1, 2004. http://
www.fda.gov/bbs/topics/news/2004/NEW01129.htlm. Accessed on October 28, 2006.
[5] Kris-Etherton, P M.; Mustad V. Derr J.A. Effects of dietary stearic acid on plasma lip‐
ids and thrombosis, Nutrition Today. 1993, 28: 30-38.
[6] Nunez, J Randon, C Gandhi, A Siafaka-Kapadai, MS Olson and DJ Hanahan: The in‐
hibition of platelet-activating factor-induced platelet activation by oleic acid is associ‐
ated with a decrease in polyphosphoinositide metabolism, Journal of Biological
Chemisty, Volume 265, n° 30, October 25, pp18330-18338, 1990.
[7] Barradas, M.A. Christofides, J.A. Jeremy, J.Y. Mikhailidis, D.P. Fry, D.E. Dandona, P.
The Effect of Olive Oil Supplementation on Human Platelet Function, Serum Choles‐
terol-Related Variables and Plasma Fibrinogen Concentrations: A Pilot Study, Nutri‐
tion Research, 1990, 10: 403-411.
[8] Teres, S. Barcelo-Coblijn, G. Benet, M. Alvarez, R. A, Bressani, R. Halver, J. E. Escriba,
P. V. Oleic acid content is responsible for the reduction in blood pressure induced by
olive oil. PNAS. 2008, 105: 13811-13816.
[9] Alemany R. Terés S., Baamonde C., Benet M., Vögler O., Escribá P. V. 2-Hydroxyoleic
Acid. A New Hypotensive Molecule, Hypertension. 2004, 43: 249-54.
[10] Cocchi, M., Tonello, L. Tsaluchidu, S. Puri, B.K. The use of artificial neural networks
to study fatty acids in neuropsychiatric disorders. BMC Psychiatry. 2008, 8(Suppl.
1):S3. doi: 10.1186/1471-244X-8-S1-S3.
[11] Donati, R.J. Dwivedi, Y. Roberts, R.C. Conley, R.R. Pandey, G.N. Rasenick, M.M.
Postmortem Brain Tissue of Depressed Suicides Reveals Increased Gs Localization in
Lipid Raft Domains Where It Is Less Likely to Activate Adenylyl Cyclase. J. Neuro‐
sci. 2008, 28:3042-3050.
[12] Hameroff, S.R. Penrose, R. Orchestrated reduction of quantum coherence in brain
microtubules: A model for consciousness. In: SR Hameroff, A Kaszniak and AC Scott
(eds.) Toward a Science of Consciousness - The First Tucson Discussions and De‐
bates. MIT Press, Cambridge, UK. 1996, 507-540.
Reduced Consumption of Olive Oil: A Risk for Ischemic Heart Disease?
http://dx.doi.org/10.5772/54035
21
[13] Hameroff, S.R. The “conscious pilot”-dendritic synchrony moves through the brain
to mediate consciousness. J. Biol. Phys. 2009, Published online: doi: 10.1007/
s10867-009-9148-x.
[14] Alberts B., Bray D., Lewis J., Raff M., Roberts K., Watson JD. Molecular Biology of the
cell. Garland Publishing, 1994.
[15] Mattson, F.H. Grundy, S. M. Comparison of effects of dietary saturated, monounsa‐
turated, and polyunsaturated fatty acids on plasma lipids and lipoproteins in man. J
Lipid Res. 1985, 26:194-202.
[16] Sirtori, C. R. Tremoli, E. Gatti, E. Montanari, G. Sirtori, M. Colli, S. Gianfranceschi, G.
Maderna, P. Dentone, C. Z. Testolin, G. Galli, C. (). Controlled evaluation of fat in‐
take in the Mediterranean diet: comparative activities of olive oil and corn oil on
plasma lipids and platelets in high-risk patients. Am. J. Clin. Nutr. 1986, 44: 635-642.
[17] Carmena, R. Ascaso, J.F. Camejo, G. Varela, G. Hurt-Camejo, E. Ordovas, J.M. Marti‐
nez-Valls, J. Bergstöm, M. Wallin, B. Effect of olive oil and sunflower oils on low den‐
sity lipoprotein level, composition, size, oxidation and interaction with arterial
proteoglycans. Atherosclerosis, 1996, 125: 243-255.
[18] Mata, P. Alvarez-Sala, L. A. Rubio, M. J. Nun O. J. De Oya, M. Effects of long-term
monounsaturated- vs polyunsaturated-enriched diets on lipoproteins in healthy men
and women. Am. J. Clin. Nutr. 1992, 55: 846–850.
[19] Nicolaïew, N. Lemort, N. Adorni, L. Berra, B. Montorfano, G. Rapelli, S. Cortesi, N.
Jacotot, B. Comparison between Extra Virgin Olive Oil and Oleic Acid Rich Sunflow‐
er Oil: Effects on Postprandial Lipemia and LDL Susceptibility to Oxidation. Ann.
Nutr. Metab. 1998, 42: 251-260.
[20] Mensink, R. De Groot, M. Vanden Broeke, L. Severigen-Nobels, A. Demacker, P. Ka‐
tan, M. Effect of monounsaturated fatty acids vs. complex carbohydrates on serum
lipoproteins and apolipoproteins in healthy men and women. Metabolism. 1989, 38:
172-178.
[21] Carmena, R. Ros, E. Gómez Gerique, J. A. Masana, L. Ascaso, J. F. Betancort, P. Eco‐
men daciones para la prevención de la arteriosclerosis en España. Documento Oficial
de la Sociedad Española de Arteriosclerosis (Recommendations for atherosclerosis
prevention in Spain). In: Official document by The Spanish Atherosclerosis Society
Clin Invest Arterios clerosis 1, 1989, 1–9.
[22] Grundy, S. M. Comparison of monounsaturated fatty acids and carbohydrates. N
Eng J Med. 1986, 314: 745-748.
[23] Grundy, S. M. Flosentin, L. Nix, D. Whelan, M. F. Comparison of monounsaturated
fatty acids and carbohydrates for reducing raised levels of plasma cholesterol in
man. Am J Clin Nutr. 1988, 47: 965-969.
What Should We Know About Prevented, Diagnostic, and Interventional Therapy in Coronary Artery Disease22
[24] Mattson, F.H. Grundy, S.M. Comparison of effects of dietary saturated, monounsatu‐
rated, and polyunsaturated fatty acids on plasma lipids and lipoproteins in man J
Lipid Res. 1985, 26: 194-202.
[25] Keys, A. Coronary heart diseases in seven countries. Circulation, 1970, 41 sppl 1: 163–
211.
[26] Ross, R. Atherosclerosis: an inflammatory disease. N Eng J Med. 1999, 340: 115–26.
[27] Dogne, J.M. de Leval, X. Hanson, J. Frederich, M. Lambermont, B. Ghuysen, A. Casi‐
ni, A. Masereel, B. Ruan, K. H., Pirotte, B. Kolh, P. New developments on thrombox‐
ane and prostacyclin modulators. Part I. Thromboxane modulators. Curr Med Chem.
2004, 11: 1223–41.
[28] Jialal, I. Devaraj, S. Venugopal, S.K. C-reactive protein: risk marker or mediator in
atherothrombosis? Hypertension, 2004, 44: 6–11.
[29] Jialal, I. Devaraj, S. Inflammation and atherosclerosis: the value of the high sensitivity
C-reactive protein assay as a risk marker. Am J Clin Pathol. 2001, 116(Sup):S108–15.
[30] Kritchevsky, S.B. Cesari, M. Pahor, M. Inflammatory markers and cardiovascular
health in older adults. Cardiovasc Res. 2005, 66: 265–75.
[31] Tzoulaki, I. Murray G.D., Lee, A.J. Rumley, A. Lowe, G.D. Fowkes, F.G. C-reactive
protein, interleukin-6, and soluble adhesion molecules as predictors of progressive
peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circu‐
lation 2005, 112: 976–83.
[32] Tsimikas, S. Philis-Tsimikas, A. Alexopoulos, S. Sigari, F. Lee, C. Reaven, P.D. LDL
isolated from Greek subjects on a typical diet or from American subjects on an oleate-
supplemented diet induces less monocyte chemotaxis and adhesion when exposed to
oxidative stress. Arterioscler Thromb.Vasc Biol. 1999, 19: 122–30.
[33] Thanos, D. Maniatis, T. NFkB: a lesson in family values. Cell, 1995, 80: 529–32.
[34] Bellido, C. Lopez-Miranda, J. Blanco-Colio, L.M. Pérez-Martínez, P. Muriana F.J.
Martín-Ventura, J.L. Marín, C. Gomez, P. Fuentes, F. Egido, J. Pérez-Jiménez, F. But‐
ter and walnuts, but not olive oil, elicit postprandial activation of nuclear transcrip‐
tion factor kappaB in peripheral blood mononuclear cells. Am J Clin Nutr. 2004, 80:
1487–91.
[35] Lee, C. Barnett, J. Reaven, P.D. Liposomes enriched in oleic acid are less susceptible
to oxidation and have less proinflammatory activity when exposed to oxidizing con‐
ditions. J Lipid Res. 1998, 39: 1239–47.
[36] Massaro, M. basta, G. Lazzerini, G. Carluccio, M. A. Bosetti, F. Solaini, G. Visioli, F.
Paolicchi, A. De Caterina, R. Quenching of intracellular ROS generation as a mecha‐
nism for oleate-induced reduction of endothelial activation and early atherogenesis.
Thromb Haemost. 2002, 88: 335–44.
Reduced Consumption of Olive Oil: A Risk for Ischemic Heart Disease?
http://dx.doi.org/10.5772/54035
23
[37] Perona, J.S. Cabello-Moruno, R. Ruız-Gutierrez, V. The role of virgin olive oil compo‐
nents in the modulation of endotelial function. J Nutr Biochem, 2006, 17: 429–45.
[38] Gardner, C.D. Kraemer, H.C. Monounsaturated versus polyunsaturated dietary fat
and serum lipids. A meta-analysis. Arterioscler Thromb Vasc Biol. 1995, 15: 1917–27.
[39] Dubois, C. Armand, M. Azais-Braesco, V. Portugal, H. Pauli, A.M. Bernard, P.M.
Latge, C. Lafont, H. Borel, P. Lairon, D. Effects of moderate amounts of emulsified
dietary fat on postprandial lipemia and lipoproteins in normolipidemic adults. Am J
Clin Nutr. 1994, 60: 374–82.
[40] Weinbrenner, T. Fitò, M. Farre-Albaladejo, M. Saez, G. Rijken, P. Tormos, C. Coolen,
S. de la Torre, R. Covas M.I. Bioavailability of phenolic compounds from olive oil
and oxidative/ antioxidant status at postprandial state in healthy humans. Drugs Exp
Clin Res. 2004, 30: 207–14.
[41] Fitò, M. Gimeno, E. Covas M.I. Mirò, E. Lòpez-Sabater, M.C. Farrè, M. de la Torre,
Jmarrugat, R. Postprandial and short-term dietary intervention effects of virgin olive
oil ingestion on the oxidative/antioxidative status. Lipids 2002, 37: 245–51.
[42] Covas, M.I. de la Torre, K. Farrè-Albaladejo, M. Kaikkonen, J. Fitò, M. Lopez-Sabater,
C. Pujadas-Bastardes, M.A. Joglar, J. Weinbrenner, T. Lamuela-Raventós, R.M., de la
Torre, R. Postprandial LDL phenolic content and LDL oxidation is modulated by
olive oil phenolic compound in humans. Free Rad Biol Med. 2006, 40: 608–16.
[43] Abia, R. Pacheco, Y.M. Perona, J.S. Montero, E. Muriana, F.J. Ruiz-Gutierrez, V. The
metabolic availability of dietary triacylglycerols from two high oleic oils during the
postprandial period does not depend on the amount of oleic acid ingested by healthy
men. J Nutr. 2001, 131: 59–65.
[44] Roche, H.M. Zampelas, A. Knapper, J.M. Webb, D. Brooks, C. Jackson, K.G. Wright,
J. W. Gould, B. J. Kafatos, A. Gibney, M.J. Williams, C.M. Effect of long-term olive oil
dietary intervention on postprandial triacylglycerol and factor VII metabolism. Am J
Clin Nutr 1998, 68: 552– 60.
[45] Williams, C.M. Dietary interventions affecting chylomicron and chylomicron rem‐
nant clearance. Atherosclerosis 1998, 141(Suppl 1):S87–92.
[46] Rivellese, A.A. Iovine, C. Ciano, O. Costagliola, L. Galasso, R. Riccardi, G. Vaccaro,
O. Nutrient determinants of postprandial triglyceride response in a population-
based sample of type II diabetic patients. Eur J Clin Nutr. 2006, 60: 1168–73.
[47] Witztum, J.L. Steinberg, D. Role of oxidized low density lipoprotein in atherogenesis.
J Clin Invest. 1991, 88: 1785–92.
[48] Navab, M. Berliner, J.A. Watson, A.D. Hama, S.Y. Territo, M.C. Lusis, A.J. Shih, D.M.
Van Lenten, B.J. Frank, J.S. Demer, L.L. Edwards, P.A. Fogelman, A.M. The Ying and
Tang of oxidation in the development of the fatty streak. Arterioscler Thromb Vasc
Biol. 1996, 16: 831–42.
What Should We Know About Prevented, Diagnostic, and Interventional Therapy in Coronary Artery Disease24
[49] Holvoet, P. Mertens, A. Verhamme, P. Bogaerts, K. Beyens, G. Verhaeghe, R. Collen,
D. Muls, E. Van de Werf, F. Circulating oxidized LDL is a useful marker for identify‐
ing patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2001, 21:
844–8.
[50] Weinbrenner, T. Cladellas, M. Covas, M.I. Fitò, M. Tomas, M. Senti, M. Bruguera, J.
Marrugat, J. High oxidative stress in patients with stable coronary heart disease.
Atherosclerosis, 2003, 168: 99–106.
[51] Liu, M.L. Ylitalo, K. Salonen, R. Salonen, J.T. Taskinen, M.R. Circulating oxidized
low-density lipoprotein and its association with carotid intima-media thickness in
asymptomatic members of familial combined hyperlipidemia families. Arterioscler
ThrombVasc Biol. 2004, 24: 1492–7.
[52] Toshima, S. Hasegawa, A. Kurabayashi, M. Itabe, H. Takano, T. Sugano, J. Shima‐
mura, K. Kimura, Michishita, J.I. Suzuki, T. Nagai, R. Circulating oxidized low densi‐
ty lipoprotein levels. A biochemical risk marker for coronary heart disease.
Arterioscler Thromb Vasc Biol 2000, 20: 2243–7.
[53] Meisinger, C. Baumert, J. Khuseyinova, N. Loewel, H. Koenig, W. Plasma oxidized
low-density lipoprotein, a strong predictor for acute coronary heart disease events
un apparently healthy, middle-aged men from the general population. Circulation,
2005, 112: 651–7.
[54] Parthasarathy, S. Khoo, J.C. Miller, E. Barnett, J. Witztum, J.L. Steinberg, D. Low den‐
sity lipoprotein rich in oleic acid is protected against oxidative modification: implica‐
tions for dietary prevention of atherosclerosis. Proc Natl Acad Sci USA. 1990, 87:
3894–8.
[55] Berry, E.M. Eisenberg, S. Harats, D. Friedlander, Y. Norman, Y. Kaufmann, N.A.
Norman, Y. Stein, Y. Effects of diets rich in monounsaturated fatty acids on plasma
lipoproteins – the Jerusalem Nutrition Study: high MUFAs vs high PUFAs. Am J Clin
Nutr.1991, 53: 899–907.
[56] Reaven, P. Parthasarathy, S. Grasse, B.J. Miller, E. Steinberg, D. Witztum, J.L. Effects
of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein
to oxidative modification in mildly hypercholesterolemic subjects. J Clin Invest. 1993,
91: 668–76.
[57] Bonanome, A. Pagnan, A. Biffanti, S. Opportuno, A. Sorgato, F. Dorella, M. Maiorino,
M. Ursini, F. Effect of dietary monounsaturated and polyunsaturated fatty acids on
the susceptibility of plasma low density lipoproteins to oxidativemodification. Arte‐
rioscler Thromb. 1992, 12: 529–33.
[58] Abbey, M. Belling, G.B. Noakes, M. Hirata, F. Nestel, P.J. Oxidation of lowdensity
lipoproteins: intraindividual variability and the effect of dietary linoleate supplemen‐
tation. Am J Clin Nutr. 1993, 57: 391–8.
Reduced Consumption of Olive Oil: A Risk for Ischemic Heart Disease?
http://dx.doi.org/10.5772/54035
25
[59] Baroni, S.S. Amelio, M. Sangiorgi, Z. Gaddi, A. Battino, M. Solid monounsaturated
diet lowers LDL unsaturation trait and oxidisability in hypercholesterolemic (type
IIb) patients. Free Radic Res. 1999, 30: 275–85.
[60] Mata, P. Varela, O. Alonso, R. Lahoz, C. de Oya, M. Badimon, L. Monounsaturated
and polyunsaturated n-6 fatty acid-enriched diets modify LDL oxidation and de‐
crease human coronary smooth muscle cell DNA synthesis. Arterioscler Thromb
Vasc Biol. 1997, 17: 2088–95.
[61] Kohonen, T. Self-Organized formation of topologically correct feature maps. Biol.
Cybern. 1982, 43: 59-69.
[62] Kohonen, T. Self-Organizing Maps. 3rd ed. Springer, 2001, Berlin, Germany.
[63] Kohonen, T. Kaski, S. Somervuo, P. Lagus, K. Oja, M. Paatero, V. Self-organizing
map, Neurocomputing, 1998. 21: 113-122.
[64] Cocchi, M. Tonello, L. Bosi, S. Cremonesi, A. Castriota, F. Puri, B. Tsaluchidu, S. Pla‐
telet oleic acid as Ischemic Cardiovascular Disease marker. BMJ. 2007, Electronic let‐
ter to the editor.
[65] Cocchi, M. Tonello, L. Cappello, G. Bosi, S. Cremonesi, A. Castriota, F. Mercante, M.
Tarozzi, G. Bochicchio, D. Della Casa, G. Caramia, G. Membrane platelet fatty acids:
a model of biochemical characterisation of the ischemic cardiovascular disease,
through an artificial neural network interpretation, Progr Nutr. 2008, 10, 1: 48-52.
[66] Cocchi, M. Tonello, L. Lercker, G. Platelet Stearic Acid in different population
groups: biochemical and functional hypothesis. Nutr. clín. diet. hosp. 2009, 29: 34-45.
[67] Tonello, L. Cappello, G. Cocchi, M. “Nutritional Effects on Cardiovascular System”,
3rd International Conference on Gravity and Cardiovascular System, 2006. INRC and
CSV Italian Air Force (Pratica di Mare Air Force Base, November 13-15).
[68] Cocchi, M. Tonello, L. Platelets, Fatty Acids, Depression and Cardiovascular Ische‐
mic Pathology, Progr Nutr. 2007, 9, 2: 94-104.
[69] Tiemeier, H. van Dijck, W. Hofman, A. Witteman, J.C.M. Stijnen, T. Breteler, M.M.B.
Relationship between Atherosclerosis and Late-Life Depression. Arch Gen Psychia‐
try, 2004, 61: 369-376.
[70] Musselman, D.L. Evans, D.L. Nemeroff, C.B. The relationship of depression to cardi‐
ovascular disease epidemiology, biology, and treatment. Archives of General Psy‐
chiatry, 1998, 55: 580-592.
[71] Weyers, J. Colquhoun, D. For the OLIVE Study Group. A Mediterranean Diet (Med)
Vs A Low Fat (Lf) Diet Improves Depression Independent of Cholesterol In Coro‐
nary Heart Disease Patients (CHD) June 29, 2000: Poster Abstracts.
[72] Cocchi, M. Mordenti, A.L. Merendi, F. Sardi, L. Tonello, L. Bochicchio, D. Faeti, V.
Della Casa, G. Pig platelet fatty acids composition in different lipid treatments. LXI
National Meeting SISVet (Salsomaggiore Terme, PR, Italy, Sep 26-29, 2007).
What Should We Know About Prevented, Diagnostic, and Interventional Therapy in Coronary Artery Disease26
[73] Nichols, T.C. du Laney, T. Zheng, B. Bellinger Dwight, A. Nickols, G.A. Engleman,
W. Clemmons, D.R. Reduction in Atherosclerotic Lesion Size in Pigs by aVb3 Inhibi‐
tors Is Associated With Inhibition of Insulin-Like Growth Factor-I–Mediated Signal‐
ing Circulation Research, 1999, 85: 1040-1045.
[74] Afri, M. Ehrenberg, B. Talmon, Y. Schmidt, J. Cohen, Y. Frimer, A.A. Active oxygen
chemistry within the liposomial bilayer. Part III: Locating vitamin E, ubiquinol and
ubiquinone and their derivatives in the lipid layer. Chem Phys Lipids, 2004, 3:
107-121.
[75] Gunstone, F.D. Harwood, J.L. Padley, F.B. The lipid handbook, Chapman & Hall Eds.
London-New York, 1986, 453-457.
[76] Belitz H-D, Grosch W, Schieberle, P. Food Chemistry, Springer Verlag Ed., Berlin,
Heidelberg, New York, London, Paris, Tokyo, 1987, 175.
[77] Wijesundera, C. Ceccato, C. Watkins, P. Fagan, P. Thienthong, N. Perlmutter, P. Do‐
cosahesaenoic acid is more stable to oxidation when located at the sn-2 position of
triacylglycerol compared to sn-1(3). J Am Chem Soc. 2008, 85: 543-548.
[78] Sørensen A.D.M., Xu X., Zhang L., Kristensen J.B., Jacobsen C. (2010) Human Milk
Fat Substitute from Butterfat: Production by Enzymatic Interesterification and Evalu‐
ation of Oxidative Stability. J. Am. Oil Chem. Soc., 87,185–194.
[79] La Rivista Italiana Delle Sostanze Grasse, 2002, Caratteristiche degli Oli e Grassi Veg‐
etali. Suppl. n. 1-2.
[80] Bockish, M. Fats and Oils Handbook, 1998, AOCS Press, Champaign, Illinois, USA.
[81] International Olive Oil Council, IOOC Norms Refined olive oil, olive oil, olive-po‐
mace-oil Purity criteria, www.oliveoilquotation.com/data/files/IOOC.
[82] Lercker, G. “I componenti minori delle sostanza grasse”. Proceedings: IV Congresso
Nazionale Acidi Grassi Polinsaturi Omega 3, CLA e Antiossidanti. Progr. Nutr. 2003,
5: 93-115.
[83] Regolamento (CEE) n. 2568/91 della Commissione dell’11 luglio 1991, relativo alle
caratteristiche degli oli d'oliva e degli oli di sansa d'oliva nonché ai metodi ad essi
attinenti, (G.U.C.E. L. 248 del 5 settembre 1991).
[84] Hove, E. L. Harris, P. L. Covitamin studies. V. The interrelation of a-tocopherol and
essential unsaturated fat acids. J. Nutrition. 1946, 31: 699-713.
[85] Cocchi, M. Tonello, L. Bio molecular considerations in Major Depression and Ische‐
mic Cardiovascular Disease. Central Nervous System Agents in Medicinal Chemis‐
try. 2010, 10: 97-107.
Reduced Consumption of Olive Oil: A Risk for Ischemic Heart Disease?
http://dx.doi.org/10.5772/54035
27

